Identifying how Pre-existing Anti-Therapeutic Antibodies (PATA) are Associated with Better Outcome in a Clinical Trial of ADCC-inducing Anti-GD2 mAb |
University of Wisconsin - Madison / Paul Sondel, MD, PhD |
Innovation Grants |
2015 |
Wisconsin |
Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas |
University of Manitoba / Tamra Werbowetski-Ogilvie, PhD |
Innovation Grants |
2017 |
Manitoba |
Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy |
University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD |
Innovation Grants |
2022 |
Wisconsin |
Enhancing Pediatric Sarcoma Immunotherapy by Drug Induced Expression of Tumor-Specific Cryptic Neoantigens |
University of Minnesota / David Largaespada, PhD |
Innovation Grants |
2016 |
Minnesota |
Inhibition of Cathepsins to Treat Neuroblastoma |
Alfred I duPont Hospital for Children / Robert Mason |
Innovation Grants |
2008 |
Delaware |
Development of the Next Generation FLT3 Inhibitors for Pediatric AML and Infant ALL |
The Johns Hopkins University School of Medicine / Donald Small, MD, PhD |
Innovation Grants |
2012 |
Maryland |
Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies |
Emory University / Christopher Porter, MD |
Innovation Grants |
2019 |
Georgia |
Pathogenesis of T-cell Acute Lymphoblastic Leukemia from Myeloproliferative Disorder |
Duke University / Motonari Kondo |
Innovation Grants |
2010 |
North Carolina |
Development of MicroRNA-Nanoparticles to Treat Childhood Acute Leukemia Carrying MLL Rearrangements |
University of Cincinnati College of Medicine / Jianjun Chen, PhD |
Innovation Grants |
2013 |
Ohio |